Citius Oncology (CTOR) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Citius Oncology (CTOR).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | ||||||||||||||
Total Revenue | 1.67M (-57.61%) | 3.94M | - | - | - | - | - | - | - | - | - | - | - | - |
Cost Of Revenue | 330K (-58.23%) | 790K | - | - | - | - | - | - | - | - | - | - | - | - |
Costof Goods And Services Sold | 330K (-58.23%) | 790K | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 1.34M (-57.46%) | 3.15M | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | ||||||||||||||
Research And Development | 1.08M (+5.88%) | 1.02M (-5.56%) | 1.08M (+14.89%) | 940K (-70.06%) | 3.14M (+149.21%) | 1.26M (-3.08%) | 1.30M (+15.04%) | 1.13M (-16.30%) | 1.35M (+17.39%) | 1.15M | - | - | - | - |
Selling General And Administrative | 24M (+726.22%) | 2.86M (+113.43%) | 1.34M (-28.72%) | 1.88M (-16.07%) | 2.24M (-32.53%) | 3.32M (-10.51%) | 3.71M (+140.91%) | 1.54M (+10.79%) | 1.39M (-8.55%) | 1.52M (+261.90%) | 420K (+110.00%) | 200K | - | - |
Operating Expenses | 30M (+256.12%) | 8.41M (+78.56%) | 4.71M (-4.66%) | 4.94M (-33.87%) | 7.47M (+16.90%) | 6.39M (-4.20%) | 6.67M (+44.06%) | 4.63M (-1.28%) | 4.69M (+2.40%) | 4.58M (+990.48%) | 420K (+110.00%) | 200K | - | - |
Operating Income | ||||||||||||||
Operating Income | -28.61M (+444.95%) | -5.25M (+11.46%) | -4.71M (-4.66%) | -4.94M (-33.87%) | -7.47M (+16.90%) | -6.39M (-59.25%) | -15.68M (+238.66%) | -4.63M (+1614.81%) | -270.00K | - | -420.00K (+110.00%) | -200.00K | - | - |
Ebit | -28.61M (+444.95%) | -5.25M (+11.46%) | -4.71M (-4.66%) | -4.94M (-33.87%) | -7.47M (+16.90%) | -6.39M (-42.38%) | -11.09M (+139.52%) | -4.63M (+1614.81%) | -270.00K (-94.10%) | -4.58M (+990.48%) | -420.00K (+110.00%) | -200.00K | - | -10.00K |
EBITDA | -26.81M (+413.60%) | -5.22M (+11.54%) | -4.68M (-5.26%) | -4.94M (-33.87%) | -7.47M (+16.90%) | -6.39M (-4.20%) | -6.67M (+44.06%) | -4.63M (-1.28%) | -4.69M (+2.40%) | -4.58M | 160K (-74.19%) | 620K | - | -10.00K |
Other Income / Expenses | ||||||||||||||
Interest Income | 40K (+33.33%) | 30K (-25.00%) | 40K | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense | 30K (-40.00%) | 50K (-16.67%) | 60K (-62.50%) | 160K | - | - | - | - | - | - | - | - | - | - |
Net Interest Income | 40K (+33.33%) | 30K | -180.00K | - | - | - | - | - | - | - | - | - | - | - |
Other Non Operating Income | 1.77M | -20.00K (-88.89%) | -180.00K | - | - | - | - | 640K (-15.79%) | 760K | - | 580K (-29.27%) | 820K | - | - |
Net Income | ||||||||||||||
Income Before Tax | -26.84M (+409.30%) | -5.27M (+11.42%) | -4.73M (-7.44%) | -5.11M (-31.59%) | -7.47M (+16.90%) | -6.39M (-4.20%) | -6.67M (+44.06%) | -4.63M (-1.28%) | -4.69M (+2.40%) | -4.58M | - | - | - | - |
Income Tax Expense | -230.00K | 260K (0.00%) | 260K (0.00%) | 260K (0.00%) | 260K (0.00%) | 260K (+85.71%) | 140K (0.00%) | 140K (0.00%) | 140K (0.00%) | 140K | - | - | - | - |
Net Income From Continuing Operations | -26.61M (+381.19%) | -5.53M (+10.60%) | -5.00M (-6.89%) | -5.37M (-30.62%) | -7.74M (+16.22%) | -6.66M (-2.20%) | -6.81M (+42.77%) | -4.77M (-1.45%) | -4.84M (+2.33%) | -4.73M | 160K (-74.19%) | 620K | - | -10.00K |
Net Income | -26.61M (+381.19%) | -5.53M (+10.60%) | -5.00M (-6.89%) | -5.37M (-30.62%) | -7.74M (+16.22%) | -6.66M (-2.20%) | -6.81M (+42.77%) | -4.77M (-1.45%) | -4.84M (+2.33%) | -4.73M | 160K (-74.19%) | 620K | - | -10.00K |